Overview

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Status:
Recruiting
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Phase:
Phase 3
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.
Collaborator:
AstraZeneca